Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753925 | 0.89 | GAA (0.70) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL7095470 | 0.84 | CYP1A1 (0.70) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL15489874 | 0.82 | GAA (0.61) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL11575897 | 0.82 | ALDH1A1 (0.62) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL410774 | 0.82 | ALDH1A1 (0.64) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL28804407 | 0.81 | HDAC1 (0.73) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL3139569 | 0.81 | POLB (0.70) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL6794740 | 0.81 | GAA (0.66) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL9843748 | 0.81 | GAA (0.66) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL6832724 | 0.81 | CYP1A1 (0.71) | GAAALDH1A1KMT2ATHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632028-B | A kind of rich preparation method for Buddhist nun of card | 上海再启生物技术有限公司 | 2019-01-22 | — | — | CN | claimed |
| CN-106632028-A | Cabozantinib preparation method | 上海再启生物技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-122036603-A | Preparation method of anti-tumor drug cabatinib | 新乡学院 | 2026-05-15 | — | — | CN | disclosed |
| CN-115160204-B | Fibroblast activation protein inhibitor and preparation method and application thereof | 山东大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-114044742-B | Chiral primary amine malonamide compound and preparation method and application thereof | 河北工业大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-115160204-A | Fibroblast activation protein inhibitor and preparation method and application thereof | 山东大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-115003307-A | Pharmaceutical composition for preventing or treating cancers associated with KRAS mutations | 伟迈可生物有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114044742-A | Chiral primary amine malonamide compound and preparation method and application thereof | 河北工业大学 | 2022-02-15 | — | — | CN | disclosed |
| CN-106632028-B | A kind of rich preparation method for Buddhist nun of card | 上海再启生物技术有限公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-106632028-A | Cabozantinib preparation method | 上海再启生物技术有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | GAA 1488/4885ALDH1A1 3087/4885HDAC3 1257/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | GAA 2824/4885ALDH1A1 3818/4885HDAC3 1876/4885 |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | GAA 2591/4885ALDH1A1 2213/4885HDAC3 588/4885 |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | GAA 3840/4885ALDH1A1 3318/4885HDAC3 32/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | GAA 3521/4885ALDH1A1 1711/4885HDAC3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.